{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:13:39Z","timestamp":1790745219368,"version":"4.1.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jbo.2019.100253","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T19:42:03Z","timestamp":1563306123000},"page":"100253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"special_numbering":"C","title":["The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond"],"prefix":"10.1016","volume":"17","author":[{"given":"Tomalika Rahmat","family":"Ullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jbo.2019.100253_bib0001","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.exphem.2006.06.017","article-title":"Chemokines in multiple myeloma","volume":"34","author":"Aggarwal","year":"2006","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.113.007724","article-title":"International union of basic and clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors","volume":"66","author":"Bachelerie","year":"2014","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.jbo.2019.100253_bib0003","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/cmi.2017.134","article-title":"Chemokines in homeostasis and diseases","volume":"15","author":"Chen","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.jbo.2019.100253_bib0004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-417197-8.00009-2","article-title":"Constitutively active chemokine CXC receptors","volume":"70","author":"Han","year":"2014","journal-title":"Adv. Pharmacol."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/wound.2012.0380","article-title":"Chemokines and their receptors are key players in the orchestra that regulates wound healing","volume":"2","author":"Martins-Green","year":"2013","journal-title":"Adv. Wound Care (New Rochelle)"},{"key":"10.1016\/j.jbo.2019.100253_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv. Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0007","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10147-017-1187-x","article-title":"Biological\/pathological functions of the CXCL12\/CXCR4\/CXCR7 axes in the pathogenesis of bladder cancer","volume":"22","author":"Nazari","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2019.100253_bib0008","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","article-title":"The biology of chemokines and their receptors","volume":"18","author":"Rossi","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jbo.2019.100253_bib0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cyto.2017.12.022","article-title":"Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3","volume":"109","author":"Murphy","year":"2018","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/B:HIJO.0000032355.66152.b8","article-title":"CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion","volume":"35","author":"Kucia","year":"2004","journal-title":"J. Mol. Histol."},{"issue":"10","key":"10.1016\/j.jbo.2019.100253_bib0011","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1074\/jbc.M109.091173","article-title":"Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling","volume":"285","author":"Busillo","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbo.2019.100253_bib0012","first-page":"4953","article-title":"CXCR4 in breast cancer: oncogenic role and therapeutic targeting","volume":"9","author":"Xu","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.jbo.2019.100253_bib0013","first-page":"144","article-title":"CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment","volume":"8","author":"Wurth","year":"2014","journal-title":"Front Cell Neurosci."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.onc.1206910","article-title":"Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells","volume":"23","author":"Fernandis","year":"2004","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.jbo.2019.100253_bib0015","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1096\/fasebj.13.13.1699","article-title":"The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK\/STAT pathway","volume":"13","author":"Vila-Coro","year":"1999","journal-title":"Faseb. J."},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0016","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2567.2004.01863.x","article-title":"Impaired chemokine-induced migration during T-cell development in the absence of JAK 3","volume":"112","author":"Soldevila","year":"2004","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0017","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1408745","article-title":"Monocytes\/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma","volume":"7","author":"Meng","year":"2018","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0018","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/IGC.0b013e31821d2543","article-title":"Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical WNT signaling pathway","volume":"21","author":"Wang","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0019","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/cdd.2011.89","article-title":"The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network","volume":"19","author":"Fareh","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbo.2019.100253_bib0020","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2407-12-480","article-title":"Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression","volume":"12","author":"Jin","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2019.100253_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biocel.2017.12.018","article-title":"The good and bad faces of the CXCR4 chemokine receptor","volume":"95","author":"Teixido","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0714.2009.00801.x","article-title":"Expression of CXCR4 in oral squamous cell carcinoma: correlations with clinicopathology and pivotal role of proliferation","volume":"39","author":"Meng","year":"2010","journal-title":"J. Oral Pathol. Med."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/annonc\/mdl342","article-title":"Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer","volume":"18","author":"Kodama","year":"2007","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2019.100253_bib0024","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1007\/s13277-013-1603-4","article-title":"The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis","volume":"35","author":"Han","year":"2014","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.jbo.2019.100253_bib0025","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/his.12321","article-title":"The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis","volume":"64","author":"Lv","year":"2014","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.jbo.2019.100253_bib0026","first-page":"340","article-title":"Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis","volume":"6","author":"Ghanem","year":"2014","journal-title":"Am. J. Transl. Res."},{"issue":"10","key":"10.1016\/j.jbo.2019.100253_bib0027","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1055-9965.EPI-10-0405","article-title":"High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma","volume":"19","author":"Liang","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0028","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7150\/jca.23042","article-title":"CXCR4\/CXCR7\/CXCL12-axis in follicular thyroid carcinoma","volume":"9","author":"Werner","year":"2018","journal-title":"J. Cancer"},{"issue":"24","key":"10.1016\/j.jbo.2019.100253_bib0029","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment","volume":"71","author":"Obermajer","year":"2011","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jbo.2019.100253_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3727\/096504014X13907540404879","article-title":"Stromal cell-derived factor-1 (SDF-1)\/CXCR4 axis enhances cellular invasion in ovarian carcinoma cells via integrin beta1 and beta3 expressions","volume":"21","author":"Yu","year":"2013","journal-title":"Oncol. Res."},{"issue":"17","key":"10.1016\/j.jbo.2019.100253_bib0031","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1158\/1078-0432.CCR-07-0859","article-title":"CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility","volume":"13","author":"Hirata","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0032","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4161\/cbt.9.6.11233","article-title":"The role of chemokine receptor CXCR4 in lung cancer","volume":"9","author":"Gangadhar","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cjp2.91","article-title":"Biomarker discovery for renal cancer stem cells","volume":"4","author":"Corro","year":"2018","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.jbo.2019.100253_bib0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1476-4598-5-56","article-title":"Stromal derived factor-1 (SDF-1\/CXCL12) and CXCR4 in renal cell carcinoma metastasis","volume":"5","author":"Pan","year":"2006","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2559.2009.03289.x","article-title":"Increased expression of SDF-1\/CXCR4 is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast","volume":"54","author":"Liu","year":"2009","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0036","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12031-013-9954-2","article-title":"The SDF-1 3\u2032A genetic variation is correlated with elevated intra-tumor tissue and circulating concentration of CXCL12 in glial tumors: a study on Iranian anaplastic astrocytoma and glioblastoma multiforme patients","volume":"50","author":"Moosavi","year":"2013","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0037","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11060-007-9349-8","article-title":"The anti-cancer compound nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells","volume":"84","author":"Ping","year":"2007","journal-title":"J. Neurooncol."},{"issue":"5","key":"10.1016\/j.jbo.2019.100253_bib0038","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-04-1887","article-title":"Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma","volume":"11","author":"Scala","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0039","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.22510","article-title":"Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype","volume":"109","author":"Konoplev","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0040","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"issue":"42","key":"10.1016\/j.jbo.2019.100253_bib0041","doi-asserted-by":"crossref","first-page":"26679","DOI":"10.18632\/oncotarget.25465","article-title":"An NFkappaB-dependent mechanism of tumor cell plasticity and lateral transmission of aggressive features","volume":"9","author":"Espinoza-Sanchez","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0042","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A review on CXCR4\/CXCL12 axis in oncology: no place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2019.100253_bib0043","first-page":"1347","article-title":"Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis","volume":"6","author":"Cojoc","year":"2013","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.jbo.2019.100253_bib0044","doi-asserted-by":"crossref","DOI":"10.1111\/boc.201800007","article-title":"Laminin alpha1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma","author":"Mammadova-Bach","year":"2018","journal-title":"Biol. Cell"},{"issue":"4","key":"10.1016\/j.jbo.2019.100253_bib0045","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1541-7786.MCR-16-0481","article-title":"Agonist-induced CXCR4 and CB2 heterodimerization inhibits Galpha13\/rhoa-mediated migration","volume":"16","author":"Scarlett","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0046","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/stemcells.2004-0342","article-title":"Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis","volume":"23","author":"Kucia","year":"2005","journal-title":"Stem Cells"},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0047","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1440-1827.2010.02548.x","article-title":"CXCR4 and cancer","volume":"60","author":"Furusato","year":"2010","journal-title":"Pathol. Int."},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0048","first-page":"1771","article-title":"Mechanisms by which CXCR4\/CXCL12 cause metastatic behavior in pancreatic cancer","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0049","doi-asserted-by":"crossref","first-page":"e90518","DOI":"10.1371\/journal.pone.0090518","article-title":"Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0050","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3892\/or.2012.2063","article-title":"Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1alpha","volume":"28","author":"Oh","year":"2012","journal-title":"Oncol. Rep."},{"issue":"23","key":"10.1016\/j.jbo.2019.100253_bib0051","doi-asserted-by":"crossref","first-page":"22473","DOI":"10.1074\/jbc.M500963200","volume":"280","author":"Phillips","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0052","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/aps.2009.204","article-title":"Transforming growth factor-beta1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells","volume":"31","author":"Zhao","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"issue":"2\u20133","key":"10.1016\/j.jbo.2019.100253_bib0053","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tox.2013.10.003","article-title":"Inhibition of CXCL12\/CXCR4 autocrine\/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity","volume":"314","author":"Gatti","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.jbo.2019.100253_bib0054","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.semcancer.2017.07.007","article-title":"Role of Forkhead Box Class O proteins in cancer progression and metastasis","volume":"50","author":"Kim","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"10.1016\/j.jbo.2019.100253_bib0055","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.21037\/jtd.2017.10.138","article-title":"Role of the stromal cell derived factor-1\/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism","volume":"9","author":"Zeng","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"29","key":"10.1016\/j.jbo.2019.100253_bib0056","doi-asserted-by":"crossref","first-page":"11470","DOI":"10.1074\/jbc.RA118.001872","article-title":"Endocytosis is required for CXC chemokine receptor type 4 (CXCR4)-mediated AKT activation and antiapoptotic signaling","volume":"293","author":"English","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0057","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-014-3053-0","article-title":"Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression","volume":"146","author":"Liang","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0058","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/pros.22795","article-title":"MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer","volume":"74","author":"Shen","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.jbo.2019.100253_bib0059","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2018.4477","article-title":"NT21MP negatively regulates paclitaxel-resistant cells by targeting miR1553p and miR155-5p via the CXCR4 pathway in breast cancer","author":"Wang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbo.2019.100253_bib0060","doi-asserted-by":"crossref","DOI":"10.3727\/096504018X15201143705855","article-title":"Knockdown of urothelial carcinoma associated 1 suppressed cell growth and migration through regulating miR-301a and CXCR4 in osteosarcoma MHCC97 cells","author":"Zhu","year":"2018","journal-title":"Oncol. Res."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072087","article-title":"Towards molecular profiling in multiple myeloma: a literature review and early indications of its efficacy for informing treatment strategies","volume":"19","author":"Willenbacher","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2019.100253_bib0062","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2018.02.020","article-title":"Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies","volume":"109","author":"Peled","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.jbo.2019.100253_bib0063","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jbo.2019.100253_bib0064","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jbo.2019.100253_bib0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fendo.2018.00313","article-title":"Role of tumor-derived chemokines in osteolytic bone metastasis","volume":"9","author":"Coniglio","year":"2018","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0066","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jbo.2019.100253_bib0067","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","article-title":"Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"05","key":"10.1016\/j.jbo.2019.100253_bib0068","doi-asserted-by":"crossref","DOI":"10.4172\/2329-8790.1000159","article-title":"Targeting CXCL12\/CXCR4 axis in multiple myeloma","volume":"02","author":"K Pandey","year":"2014","journal-title":"J. Hematol. Thromboembol. Diseases"},{"issue":"24","key":"10.1016\/j.jbo.2019.100253_bib0069","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0070","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/10428190902893801","article-title":"Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells","volume":"50","author":"Kim","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.jbo.2019.100253_bib0071","article-title":"Mechanisms regulating CXCR4 expression in myeloma cells","volume":"110","author":"Kim","year":"2007","journal-title":"Blood."},{"issue":"20","key":"10.1016\/j.jbo.2019.100253_bib0072","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2alpha promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.jbo.2019.100253_bib0073","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.4049\/jimmunol.1302209","article-title":"MIF promotes b cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling","volume":"192","author":"Klasen","year":"2014","journal-title":"J. Immunol."},{"issue":"30","key":"10.1016\/j.jbo.2019.100253_bib0074","doi-asserted-by":"crossref","first-page":"15881","DOI":"10.1074\/jbc.M116.717751","article-title":"Macrophage migration inhibitory factor-CXCR4 receptor Interactions: evidence for partial allosteric agonism in comparison with CXCL12 chemokine","volume":"291","author":"Rajasekaran","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.jbo.2019.100253_bib0075","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw131","article-title":"Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response","volume":"108","author":"Zheng","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0076","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12943-016-0552-0","article-title":"Pharmacological targeting of CXCL12\/CXCR4 signaling in prostate cancer bone metastasis","volume":"15","author":"Conley-LaComb","year":"2016","journal-title":"Mol. Cancer"},{"issue":"42","key":"10.1016\/j.jbo.2019.100253_bib0077","doi-asserted-by":"crossref","first-page":"35760","DOI":"10.1074\/jbc.M508234200","article-title":"The chemokine SDF-1\/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes","volume":"280","author":"Balabanian","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.jbo.2019.100253_bib0078","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2019.100253_bib0079","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coi.2015.01.017","article-title":"Differentiation and maintenance of long-lived plasma cells","volume":"33","author":"Kometani","year":"2015","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.14807","article-title":"CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma","volume":"179","author":"Waldschmidt","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0081","first-page":"539","article-title":"The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma","volume":"1","author":"Hideshima","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0082","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.yexcr.2003.12.003","article-title":"Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion","volume":"294","author":"Parmo-Cabanas","year":"2004","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jbo.2019.100253_bib0083","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/1471-2407-11-301","article-title":"Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model","volume":"11","author":"Follin-Arbelet","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2019.100253_bib0084","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1038\/oncsis.2016.5","article-title":"Heparanase-induced shedding of syndecan-1\/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins","volume":"5","author":"Jung","year":"2016","journal-title":"Oncogenesis"},{"issue":"29","key":"10.1016\/j.jbo.2019.100253_bib0085","doi-asserted-by":"crossref","first-page":"26826","DOI":"10.18632\/oncotarget.5025","article-title":"Notch signaling deregulation in multiple myeloma: a rational molecular target","volume":"6","author":"Colombo","year":"2015","journal-title":"Oncotarget"},{"issue":"35","key":"10.1016\/j.jbo.2019.100253_bib0086","doi-asserted-by":"crossref","first-page":"14062","DOI":"10.1073\/pnas.0705203104","article-title":"Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone","volume":"104","author":"Hirbe","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0087","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clml.2017.09.020","article-title":"Two states of myeloma stem cells","volume":"18","author":"Yaccoby","year":"2018","journal-title":"Clin. Lymph. Myeloma. Leuk."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0088","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jbo.2019.100253_bib0089","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.matbio.2014.03.001","article-title":"Role of osteopontin in the pathophysiology of cancer","volume":"37","author":"Samant","year":"2014","journal-title":"Matrix Biol."},{"issue":"13","key":"10.1016\/j.jbo.2019.100253_bib0090","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa b ligand (RANKL) in t lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0091","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1359\/jbmr.090503","article-title":"CXCL12\/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma","volume":"24","author":"Ooi","year":"2009","journal-title":"J. Bone Miner Res."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0092","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12185-016-2104-1","article-title":"Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?","volume":"105","author":"Marchica","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"11","key":"10.1016\/j.jbo.2019.100253_bib0093","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/ijc.26031","article-title":"The seed and soil hypothesis revisited\u2013the role of tumor-stroma interactions in metastasis to different organs","volume":"128","author":"Langley","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0094","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a model for the process of metastasis: implications for therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbo.2019.100253_bib0095","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0096","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2019.100253_bib0097","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.2147\/OTT.S135867","article-title":"The RANK\/RANKL\/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy","volume":"10","author":"Sisay","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.jbo.2019.100253_bib0098","first-page":"471","article-title":"The role of RANK\/RANKL and OPG in multiple myeloma","volume":"60","author":"Zdzisinska","year":"2006","journal-title":"Postepy Hig. Med. Dosw. (Online)"},{"key":"10.1016\/j.jbo.2019.100253_bib0099","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2017.02.032","article-title":"Osteoprotegerin regulates cancer cell migration through SDF-1\/CXCR4 axis and promotes tumour development by increasing neovascularization","volume":"395","author":"Benslimane-Ahmim","year":"2017","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.jbo.2019.100253_bib0100","first-page":"391","article-title":"Multiple myeloma and diagnostic imaging","volume":"85","author":"Reisenbuckler","year":"2014","journal-title":"Radiol. Technol."},{"key":"10.1016\/j.jbo.2019.100253_bib0101","article-title":"Tumor cell dormancy","author":"Gomis","year":"2016","journal-title":"Mol. Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0102","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/0008-5472.CAN-17-2446","article-title":"Myeloma cells are activated in bone marrow microenvironment by the CD180\/MD-1 complex, which senses lipopolysaccharide","volume":"78","author":"Kikuchi","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2019.100253_bib0103","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.jbo.2019.100253_bib0104","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/BF03349262","article-title":"The critical role of SDF-1\/CXCR4 axis in cancer and cancer stem cells metastasis","volume":"31","author":"Gelmini","year":"2008","journal-title":"J. Endocrinol. Invest."},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.13384","article-title":"Extramedullary disease in multiple myeloma in the era of novel agents","volume":"169","author":"Blade","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.jbo.2019.100253_bib0106","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2013.148","article-title":"Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib","volume":"27","author":"Stessman","year":"2013","journal-title":"Leukemia"},{"issue":"5320","key":"10.1016\/j.jbo.2019.100253_bib0107","article-title":"CXCR4 is a regulator of disease involvement of extramedullary myeloma confirmed by a novel mouse model for extramedullary disease","volume":"122","author":"Yuji Mishima","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2019.100253_bib0108","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood.V124.21.4709.4709","article-title":"Novel CXCR4-Targeted therapy to inhibit multiple myeloma bone dissemination","volume":"124","author":"Roccaro","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2019.100253_bib0109","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1038\/bcj.2015.46","article-title":"Targeting the PIM kinases in multiple myeloma","volume":"5","author":"Keane","year":"2015","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/leu.2017.287","article-title":"JAM-A as a prognostic factor and new therapeutic target in multiple myeloma","volume":"32","author":"Solimando","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0111","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/stem.2340","article-title":"Junctional adhesion molecule \u2013 a is highly expressed on human hematopoietic repopulating cells and associates with the key hematopoietic chemokine receptor CXCR4","volume":"34","author":"Chang","year":"2016","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","article-title":"Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors","volume":"9","author":"Turner","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"15","key":"10.1016\/j.jbo.2019.100253_bib0113","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/bloodadvances.2016003921","article-title":"A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies","volume":"1","author":"Liu","year":"2017","journal-title":"Blood Adv."},{"issue":"5315","key":"10.1016\/j.jbo.2019.100253_bib0114","article-title":"The myeloma cells escape from bone marrow to skin extramedullary localization upon bortezomib resistance: role of CXCR4","volume":"126","author":"Valentina Marchica","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2019.100253_bib0115","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2018.04","article-title":"Drug targets and resistance mechanisms in multiple myeloma","author":"Nass","year":"2018","journal-title":"Cancer Drug Resist."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0116","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.exphem.2013.03.002","article-title":"HGF and IGF-1 synergize with SDF-1alpha in promoting migration of myeloma cells by cooperative activation of p21-activated kinase","volume":"41","author":"Ro","year":"2013","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0117","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12185-016-2048-5","article-title":"Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma","volume":"104","author":"Furukawa","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0118","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1007\/s13277-015-4761-8","article-title":"RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines","volume":"37","author":"Tsubaki","year":"2016","journal-title":"Tumour Biol."},{"issue":"12","key":"10.1016\/j.jbo.2019.100253_bib0119","doi-asserted-by":"crossref","first-page":"898","DOI":"10.14348\/molcells.2016.0210","article-title":"Highly expressed Integrin-alpha8 induces epithelial to mesenchymal transition-like features in multiple myeloma with early relapse","volume":"39","author":"Ryu","year":"2016","journal-title":"Mol. Cells"},{"issue":"37","key":"10.1016\/j.jbo.2019.100253_bib0120","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: emerging new players","volume":"7","author":"Di Marzo","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jbo.2019.100253_bib0121","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2007-07-102632","article-title":"Inhibition of notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy","volume":"111","author":"Nefedova","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jbo.2019.100253_bib0122","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms","volume":"4","author":"Abdi","year":"2013","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0123","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy","volume":"9","author":"Roccaro","year":"2014","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0124","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/bmt.2009.142","article-title":"Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients","volume":"45","author":"Fruehauf","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jbo.2019.100253_bib0125","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.exphem.2006.06.003","article-title":"The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics","volume":"34","author":"Fruehauf","year":"2006","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.jbo.2019.100253_bib0126","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3109\/14653240903121245","article-title":"A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study","volume":"11","author":"Fruehauf","year":"2009","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0127","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.5376","article-title":"Small molecule inhibitors of CXCR4","volume":"3","author":"Debnath","year":"2013","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canlet.2015.11.028","article-title":"Targeting SDF-1 in multiple myeloma tumor microenvironment","volume":"380","author":"Bouyssou","year":"2016","journal-title":"Cancer Lett."},{"issue":"18","key":"10.1016\/j.jbo.2019.100253_bib0129","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13045-017-0435-x","article-title":"Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia","volume":"10","author":"Kashyap","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0131","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1078-0432.CCR-13-1302","article-title":"The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma","volume":"20","author":"Peled","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0132","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2010.11.010","article-title":"CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth","volume":"39","author":"Beider","year":"2011","journal-title":"Exp. Hematol."},{"issue":"976567","key":"10.1016\/j.jbo.2019.100253_bib0133","first-page":"1","article-title":"Molecularly targeted therapies in multiple myeloma","volume":"2014","author":"Pilar de la Puente","year":"2014","journal-title":"Leuk. Res. Treatment."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0134","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-013-1910-2","article-title":"A phase 1\/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma","volume":"93","author":"Berenson","year":"2014","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jbo.2019.100253_bib0136","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2019.100253_bib0137","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.jbo.2019.100253_bib0138","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1078-0432.CCR-12-2333","article-title":"BMS-936564\/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies","volume":"19","author":"Kuhne","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0139","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives","volume":"30","author":"Lonial","year":"2016","journal-title":"Leukemia"},{"issue":"4009","key":"10.1016\/j.jbo.2019.100253_bib0140","article-title":"CXCR4 monoclonal antibody, BMS-936564 (MDX-1338), modulates epithelial to mesenchymal transition (EMT) in multiple myeloma cells","volume":"120","author":"Cardarelli","year":"2012","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.jbo.2019.100253_bib0141","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1158\/1535-7163.MCT-16-0041","article-title":"A new Anti-CXCR4 antibody that blocks the CXCR4\/SDF-1 axis and mobilizes effector cells","volume":"15","author":"Broussas","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"35","key":"10.1016\/j.jbo.2019.100253_bib0142","doi-asserted-by":"crossref","first-page":"23890","DOI":"10.18632\/oncotarget.25156","article-title":"Phase i dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma","volume":"9","author":"Fouquet","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0143","article-title":"Inhibition of CXCR4 by LY2624587, a fully humanized anti-CXCR4 antibody induces apoptosis of hematologic malignancies","volume":"11","author":"Sheng-Bin Peng","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0144","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0145","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/cam4.1085","article-title":"Inhibition of CXCL12\/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma","volume":"6","author":"Xue","year":"2017","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.jbo.2019.100253_bib0146","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.leukres.2008.09.018","article-title":"Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients","volume":"33","author":"Oliveira","year":"2009","journal-title":"Leuk Res."},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0147","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/bjh.12226","article-title":"Potentin vitroandin vivoactivity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization","volume":"161","author":"Udi","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.jbo.2019.100253_bib0148","doi-asserted-by":"crossref","first-page":"e23741","DOI":"10.1371\/journal.pone.0023741","article-title":"Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis","volume":"6","author":"Badr","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jbo.2019.100253_bib0149","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1189\/jlb.2MR1115-521RR","article-title":"Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4","volume":"99","author":"Zirafi","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"34","key":"10.1016\/j.jbo.2019.100253_bib0150","doi-asserted-by":"crossref","first-page":"35137","DOI":"10.18632\/oncotarget.6037","article-title":"EPI-X4, a novel endogenous antagonist of CXCR4","volume":"6","author":"Buske","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0151","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/bmt.2009.119","article-title":"Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization","volume":"45","author":"Dugan","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"515","key":"10.1016\/j.jbo.2019.100253_bib0152","article-title":"A phase II, open-label pilot study to evaluate the hematopoietic stem cell mobilization of TG-0054 combined with G-CSF in 12 patients with multiple myeloma, Non-Hodgkin Lymphoma or Hodgkin Lymphoma \u2013 an Interim Analysis","volume":"126","author":"Gayatri Setia","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2019.100253_bib0153","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","article-title":"Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4","volume":"26","author":"Rettig","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2019.100253_bib0154","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/835138","article-title":"New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients","volume":"2014","author":"Angelopoulou","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.jbo.2019.100253_bib0155","first-page":"e85061","article-title":"Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma","volume":"21","author":"Imai","year":"2016","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.jbo.2019.100253_bib0156","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/157489212801820039","article-title":"CXCR4 inhibitors: tumor vasculature and therapeutic challenges","volume":"7","author":"de Nigris","year":"2012","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.jbo.2019.100253_bib0157","doi-asserted-by":"crossref","first-page":"37827","DOI":"10.1038\/srep37827","article-title":"CXCR4\/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jbo.2019.100253_bib0158","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/stem.2054","article-title":"Concise Review: CXCR4\/CXCL12 signaling in immature hematopoiesis\u2013lessons from pharmacological and genetic models","volume":"33","author":"Karpova","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.jbo.2019.100253_bib0159","article-title":"Molecularly targeted therapies in multiple myeloma","volume":"2014","author":"de la Puente","year":"2014","journal-title":"Leuk. Res. Treatment"},{"issue":"37","key":"10.1016\/j.jbo.2019.100253_bib0160","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1073\/pnas.0702229104","article-title":"Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12\/SDF-1 receptor, CXCR7","volume":"104","author":"Sierro","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137419301368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137419301368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:17:54Z","timestamp":1761941874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137419301368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":160,"alternative-id":["S2212137419301368"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100253","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100253"}}